Roche Holdings Ltd ADR (RHHBY)

$52.53 -0.06 (-0.10%)
Market Cap 327.01B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 17.42
Profit Margin 13.27%
Debt to Equity Ratio 1.00
Volume 655,037
Avg Vol 2,340,502
Day's Range N/A - N/A
Shares Out 6.36B
Stochastic %K 100%
Beta 0.45
Analysts Sell
Price Target $51.58

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 24 at 4:00 PM
$SLS 2nd Day in a Row, Cracked the 52 week High -- you see what's happening - and it is exactly what you would like to see ahead of the Phase 3 Results. - the Share Price will Continue Climbing Until it absolutely Launches PSA: Industry Players $ABBV $BMY $RHHBY KNOW precisely how their Drugs - AzaVEN - Best Available Treatment BAT perform for the SLS Phase 3 Control Arm Patients - 2 AzaVEN Phase 3 Trials Have recently FAILED - AML Maintenance Trials VIALE-M - AML First Remission Maintenance Trial TERMINATED due to Toxicity VIALE-T - AML Post Transplant Maintenance Trial Terminated due to Toxicity. --- and SLS Mcap is Now Up 500% Since the IDMC Unblinded the INTERIM ALL Pooled Phase 3 MOS and IR DATA. Institutional Funds are up to 154 last report (its more now), up from just 39, when the IDMC Unblinded ActualPhase 3 MOS DATA. Call to Put ratio is 99.99 to 0.01 SLS had 13M in Cash its Now $74M Runway into 2028.
0 · Reply
EWMInteractive
EWMInteractive Dec. 23 at 10:47 AM
https://youtu.be/pvYXZo61lYc $RHHBY
0 · Reply
EWMInteractive
EWMInteractive Dec. 23 at 9:22 AM
$RHHBY https://ewminteractive.com/doubting-longevity-roche-stock-recovery #elliottwave
0 · Reply
topstockalerts
topstockalerts Dec. 19 at 8:56 PM
The Trump administration announced new drug-pricing agreements with nine major pharmaceutical companies, expanding earlier deals with Pfizer, Eli Lilly, and others. Participating companies agreed to cut Medicaid drug prices to match international levels and offer large discounts to cash-paying customers through a federal website, TrumpRx. gov. Future drugs launched in the U.S. would also be priced in line with other developed countries. In exchange, the White House granted the companies a three-year exemption from sector-specific drug tariffs. The deals include firms such as Sanofi, Novartis, Merck, Bristol Myers Squibb, Gilead, Amgen, and Roche’s Genentech. Johnson & Johnson is expected to announce a separate agreement later. The agreements push the U.S. system further toward direct-to-consumer drug sales, which drugmakers favor because they bypass pharmacy benefit managers and preserve margins. $LLY $MRK $BMY $RHHBY
0 · Reply
Quantumup
Quantumup Dec. 19 at 4:09 PM
BofA⬆️ $MLYS's PT to $46 from $43/reiterated at Buy. $AZN $ALNY - $RHHBY $NVS Stifel⬆️PT to $52 from $45 and reiterated at Buy. Here's what Stifel had to say in its note: https://x.com/Quantumup1/status/2002047867654136129?s=20
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 19 at 1:19 AM
$LMDX $FCN $LMDX $RHHBY $SPY @ar_mando IMO This was highly coordinated, but not flawless. Key steps were either overlooked or underestimated, particularly the assumption that retail shareholders would not track entity changes, IP movement, or timing inconsistencies. There is a narrative on $LMDX Stocktwits that LumiraDx management was acting in shareholders’ interests. The record does not support that view. Perhaps trying to prolong time. At no point were retail shareholders treated as stakeholders to be protected. In my opinion, this was a deliberate asset repositioning executed ahead of insolvency, with R&D funded by public investors and the balance sheet later cleared through selective transactions. The outcome speaks for itself: shareholders absorbed the losses, while valuable technology, talent, and future upside continued elsewhere, untethered from any obligation to those who financed its development.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 18 at 11:16 PM
$FCN $LMDX $RHHBY $SPY @ar_mando IMO This was highly coordinated, but not flawless. Key steps were either overlooked or underestimated, particularly the assumption that retail shareholders would not track entity changes, IP movement, or timing inconsistencies. There is a narrative on $LMDX Stocktwits that LumiraDx management was acting in shareholders’ interests. The record does not support that view. Perhaps trying to prolong time. At no point were retail shareholders treated as stakeholders to be protected. In my opinion, this was a deliberate asset repositioning executed ahead of insolvency, with R&D funded by public investors and the balance sheet later cleared through selective transactions. The outcome speaks for itself: shareholders absorbed the losses, while valuable technology, talent, and future upside continued elsewhere, untethered from any obligation to those who financed its development.
1 · Reply
Dww0311
Dww0311 Dec. 18 at 5:14 PM
$LMDX $RHHBY $FCN $SPY Believe whatever gets you through the day. This was a garden variety default & seizure followed by a negotiated sale. ALL of the shareholders were wiped out.
0 · Reply
ar_mando
ar_mando Dec. 18 at 5:13 PM
$FCN $LMDX $RHHBY $SPY no I dissagre. This case is different. This was criminal insider’s play. They knew what they are doing and where it leads. It was well planned between ron bill roche. And don’t tell me that I’m wrong. There’s no way bill lost his 20M. Neither ron. They all got what they wanted. 
0 · Reply
Dww0311
Dww0311 Dec. 18 at 3:55 PM
$LMDX $RHHBY $FCN $SPY This is what happens when a company borrows orders of magnitude more money than it can afford to service, grants its lender a blanket lien on its assets, and then defaults. It does not matter what the assets were hypothetically worth - or more to the point what you are obsessed with believing they hypothetically were worth. The only thing that matters is that the lender seized the assets. From that point forward those assets belonged to them - to sell / dispose of as they pleased, at whatever value they wished. At that precise second Lumira became an assetless shell with no value. You still don't grasp what happened here ...
0 · Reply
Latest News on RHHBY
No data available.
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 24 at 4:00 PM
$SLS 2nd Day in a Row, Cracked the 52 week High -- you see what's happening - and it is exactly what you would like to see ahead of the Phase 3 Results. - the Share Price will Continue Climbing Until it absolutely Launches PSA: Industry Players $ABBV $BMY $RHHBY KNOW precisely how their Drugs - AzaVEN - Best Available Treatment BAT perform for the SLS Phase 3 Control Arm Patients - 2 AzaVEN Phase 3 Trials Have recently FAILED - AML Maintenance Trials VIALE-M - AML First Remission Maintenance Trial TERMINATED due to Toxicity VIALE-T - AML Post Transplant Maintenance Trial Terminated due to Toxicity. --- and SLS Mcap is Now Up 500% Since the IDMC Unblinded the INTERIM ALL Pooled Phase 3 MOS and IR DATA. Institutional Funds are up to 154 last report (its more now), up from just 39, when the IDMC Unblinded ActualPhase 3 MOS DATA. Call to Put ratio is 99.99 to 0.01 SLS had 13M in Cash its Now $74M Runway into 2028.
0 · Reply
EWMInteractive
EWMInteractive Dec. 23 at 10:47 AM
https://youtu.be/pvYXZo61lYc $RHHBY
0 · Reply
EWMInteractive
EWMInteractive Dec. 23 at 9:22 AM
$RHHBY https://ewminteractive.com/doubting-longevity-roche-stock-recovery #elliottwave
0 · Reply
topstockalerts
topstockalerts Dec. 19 at 8:56 PM
The Trump administration announced new drug-pricing agreements with nine major pharmaceutical companies, expanding earlier deals with Pfizer, Eli Lilly, and others. Participating companies agreed to cut Medicaid drug prices to match international levels and offer large discounts to cash-paying customers through a federal website, TrumpRx. gov. Future drugs launched in the U.S. would also be priced in line with other developed countries. In exchange, the White House granted the companies a three-year exemption from sector-specific drug tariffs. The deals include firms such as Sanofi, Novartis, Merck, Bristol Myers Squibb, Gilead, Amgen, and Roche’s Genentech. Johnson & Johnson is expected to announce a separate agreement later. The agreements push the U.S. system further toward direct-to-consumer drug sales, which drugmakers favor because they bypass pharmacy benefit managers and preserve margins. $LLY $MRK $BMY $RHHBY
0 · Reply
Quantumup
Quantumup Dec. 19 at 4:09 PM
BofA⬆️ $MLYS's PT to $46 from $43/reiterated at Buy. $AZN $ALNY - $RHHBY $NVS Stifel⬆️PT to $52 from $45 and reiterated at Buy. Here's what Stifel had to say in its note: https://x.com/Quantumup1/status/2002047867654136129?s=20
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 19 at 1:19 AM
$LMDX $FCN $LMDX $RHHBY $SPY @ar_mando IMO This was highly coordinated, but not flawless. Key steps were either overlooked or underestimated, particularly the assumption that retail shareholders would not track entity changes, IP movement, or timing inconsistencies. There is a narrative on $LMDX Stocktwits that LumiraDx management was acting in shareholders’ interests. The record does not support that view. Perhaps trying to prolong time. At no point were retail shareholders treated as stakeholders to be protected. In my opinion, this was a deliberate asset repositioning executed ahead of insolvency, with R&D funded by public investors and the balance sheet later cleared through selective transactions. The outcome speaks for itself: shareholders absorbed the losses, while valuable technology, talent, and future upside continued elsewhere, untethered from any obligation to those who financed its development.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 18 at 11:16 PM
$FCN $LMDX $RHHBY $SPY @ar_mando IMO This was highly coordinated, but not flawless. Key steps were either overlooked or underestimated, particularly the assumption that retail shareholders would not track entity changes, IP movement, or timing inconsistencies. There is a narrative on $LMDX Stocktwits that LumiraDx management was acting in shareholders’ interests. The record does not support that view. Perhaps trying to prolong time. At no point were retail shareholders treated as stakeholders to be protected. In my opinion, this was a deliberate asset repositioning executed ahead of insolvency, with R&D funded by public investors and the balance sheet later cleared through selective transactions. The outcome speaks for itself: shareholders absorbed the losses, while valuable technology, talent, and future upside continued elsewhere, untethered from any obligation to those who financed its development.
1 · Reply
Dww0311
Dww0311 Dec. 18 at 5:14 PM
$LMDX $RHHBY $FCN $SPY Believe whatever gets you through the day. This was a garden variety default & seizure followed by a negotiated sale. ALL of the shareholders were wiped out.
0 · Reply
ar_mando
ar_mando Dec. 18 at 5:13 PM
$FCN $LMDX $RHHBY $SPY no I dissagre. This case is different. This was criminal insider’s play. They knew what they are doing and where it leads. It was well planned between ron bill roche. And don’t tell me that I’m wrong. There’s no way bill lost his 20M. Neither ron. They all got what they wanted. 
0 · Reply
Dww0311
Dww0311 Dec. 18 at 3:55 PM
$LMDX $RHHBY $FCN $SPY This is what happens when a company borrows orders of magnitude more money than it can afford to service, grants its lender a blanket lien on its assets, and then defaults. It does not matter what the assets were hypothetically worth - or more to the point what you are obsessed with believing they hypothetically were worth. The only thing that matters is that the lender seized the assets. From that point forward those assets belonged to them - to sell / dispose of as they pleased, at whatever value they wished. At that precise second Lumira became an assetless shell with no value. You still don't grasp what happened here ...
0 · Reply
Quantumup
Quantumup Dec. 18 at 1:45 PM
TD Cowen🏁 $RAPT at a Buy rating. $RHHBY - $NVS $DBVT $AZN Here's what TD Cowen said in its initiation report: RAPT's ozureprubart (IgE mAb) is an improved version of Xolair for food allergy and CSU with less frequent dosing & broader efficacy. Chinese Ph2 CSU data confirm comparable/better efficacy vs Xolair with 16-wk durability, teeing up for potential global Ph3 start by YE26. Ph2b PrestlgE food allergy trial ongoing with data in H1:27. With validated MoA and multi-blockbuster potential, initiate Buy.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 18 at 8:18 AM
$LMDX $RHHBY $FCN
0 · Reply
PickAlpha
PickAlpha Dec. 18 at 12:36 AM
PickAlpha Mid-Day: Pharma “price deals” are a valuation reset, not a headline $NVS $RHHBY $XLV White House is expected to announce drug-pricing deals with Novartis and Roche as soon as Friday, with others potentially included. The pitch is familiar: lower prices in select channels/programs in exchange for tariff/regulatory relief and de-escalation with Switzerland. Our view is this is a multiple compression event for large-cap pharma — less about one quarter’s revenue, more about the market re-pricing US “pricing power” as a policy variable. Winners are the names that can trade a contained concession (narrow scope, limited products, time-bounded) for certainty; losers are companies with US-heavy mix + high list-price exposure where “voluntary” quickly becomes a template. If this expands beyond a couple of deals, expect defensive rotation inside healthcare: higher-quality, diversified pipelines hold up; single-asset/high-US-exposure gets hit first.
0 · Reply
AustinBlack202
AustinBlack202 Dec. 17 at 8:51 PM
$LMDX $LMDX $RHHBY $FCN $SPY
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 17 at 8:42 PM
$LMDX 👁️👁️$LMDX $RHHBY $FCN $SPY Others 👀
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 17 at 8:41 PM
$LMDX 👁️👁️$LMDX $RHHBY $FCN $SPY
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 17 at 8:40 PM
$LMDX $RHHBY $FCN $SPY Others 👀
0 · Reply
Quantumup
Quantumup Dec. 17 at 4:46 PM
Piper Sandler Named $ARWR a 2026 Top Pick/⬆️PT to $100/reit'd @ OW $IONS $WVE $RHHBY REGN $TEVA Piper Sandler said in its note to investors: Naming ARWR a Top Pick for 2026 for Redemplo Launch and SHTG Data Arrowhead has launched Redemplo in Familial Chylomicronemia Syndrome. We forecast U.S. FCS sales of at least $625,000 in 4Q:25 and $12.3 million in 2026, which could prove conservative based on Redemplo's superior potency, less frequent quarterly dosing and lower annual price of $60,000 vs. IONIS' (IONS, Bratzel) Tryngolza. We are confident Arrowhead will report positive Phase III Redemplo data in SHTG in 3Q:26 with potential blockbuster label expansion in 2027. Arrowhead expects to report initial ARO-INHBE data in January, ARO-ALK7 and ARO-DIMER-PA in mid'26 and potentially ARO-MAPT data in 2026. Arrowhead holds pro forma cash of ~$1.18 billion to fund operations into 2028. We reiterate our Overweight rating and are increasing our target to $100 from $70 by adding pipeline value.
0 · Reply
Quantumup
Quantumup Dec. 17 at 12:59 PM
Leerink⬆️ $CELC's PT to $118 from $97 and reiterated at an Outperform rating after Updating its Model Post-SABCS. $RHHBY $NVS $AZN $LLY PFE Leerink said in its note: Bottom Line: Exiting the San Antonio Breast Cancer Symposium (SABCS), we believe gedatolisib's (geda) robust Ph 3 data in PIK3CA wild-type (WT) HR+ HER2- breast cancer patients will lead to a favorable readout for the upcoming PIK3CA mutant (MT) cohort in 1Q/2Q26. We also see the Ph 3 evERA results supportive of a label limited to ESR1 mutant (ESR1m) patients, not posing a threat to geda (see notes here and here), which eventually could be combined with an oral SERD partner. We have also adjusted our estimates to reflect currently the issued patents, resulting in exclusivity through 2042. The patent estate consists of a composition of matter patent (2034), the cyclodextrin formulation patent (2041), and the dosage regimen patent (2042). The net of our changes increases our PT to $118 PT. Reiterate OP.
0 · Reply
Biotech_Beast
Biotech_Beast Dec. 16 at 10:02 PM
$AUPH has continued to run despite the approval of $RHHBY 's Gazyva for lupus nephritis, and an FDA request for information. I took a look. https://seekingalpha.com/article/4853816-aurinia-pharmaceuticals-silencing-doubters-but-competition-looms
1 · Reply
MQuick
MQuick Dec. 16 at 6:40 PM
$GANX its $RHHBY
1 · Reply
MQuick
MQuick Dec. 16 at 2:40 PM
$GANX lets go $RHHBY its time!
0 · Reply